The safety and effectiveness of the application of toluene sulfonate rematopolinin in the elderly painless gastroscopy combined with propylene fat

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038026

Enrollment

Unknown

Registered

2020-09-08

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopic anesthesia

Interventions

Benzodiazepine (RGroup):Benzodiazepine

Etomidate combined with propofol (EP Group):Etomidate combined with propofol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age 60 to 75 years old, gender-neutral; (2) BMI 18-27.5kg/m2; (3)ASA I-II; (4) Patients who undergo a routine gastroscopy and are well aware and volunteer to participate in the program; (5) The gastric mirror operation time is not expected to exceed 15 minutes.

Exclusion criteria

Exclusion criteria: (1) Patients with acute upper respiratory tractinfection asthma attack or acute severe throat disease; (2) Patients with low blood pressure and severe uncontrolled hypertension; (3) Unexplained pathological obesity in patients; (4) Patients with liver dysfunction (Grade B); (5) Patients with acute upper digestive tract hemorrhage or perforation; (6) Heart disease such as severe arrhythmic arrhythmic infarction is less than or equal to 6 months; (7) Patients with severe anemia (Hb less than 70g); (8) Patients with claustrophobia obstruction and retention of stomach contents; (9) Patients with severe mental illness and mental disorders who are unable to cooperate; (10) Patients with a history of drug allergies and long-term sedative analgesics; (11) Patients with adrenal corttic dysfunsis; (12) Patients with severe muscle weakness; (13) Blood sugar is not controlled in diabetic patients; (14) Wake up after surgery, delayed by more than 5 minutes, depending on the situation to give flumasinigy resistance.

Design outcomes

Primary

Measure	Time frame
Throat reflexes;Facial expressions;Body movement;	—

Secondary

Measure	Time frame
Vital signs;adverse events in surgery;Consciousness disappearance time;Awakening time;Physician satisfaction;	—

Countries

China

Contacts

Public Contactchentaichang

The First Affiliated Hospital of Guizhou University of traditional Chinese Medicine

491938581@qq.com+86 13985144433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026